- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Omeros Corporation (OMER)
The Omeros share price today is 14.600, view NASDAQ OMER stock exchange data. Track the latest Omeros share price with real-time updates on OMER stock performance including market cap, day range, 52-week range and dividend yield. Access OMER charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.575
14.920
52 wk Range
2.950
17.650
Earnings results expected in 12 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.57514.920
52 wk Range
2.95017.650
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
OMER Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
38.000
Upside
+160.27%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
- Form 13G OMEROS CORP For: 23 April
- Investing.com
- Form 13G OMEROS CORP For: 23 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
Analyst Ratings
2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 38.000
(+160.27% Upside)
Omeros Corporation Earnings Call Summary for Q4/2025
- Omeros reported Q4 2025 EPS of $3.14, vastly exceeding forecast of -$0.52, marking a 703.85% earnings surprise and significant turnaround.
- Net income reached $86.5M driven by YARTEMLEA commercial launch and $237.6M gain from Zaltenibart transaction with Novo Nordisk.
- Stock rose 2.45% aftermarket to $10.05; shares appreciated from $4.10 to $17.18 during Q4 2025 despite 39% year-to-date decline.
- Company projects YARTEMLEA program financial self-sustainability in 2026 with positive cash flow expected by 2027.
- Operating expenses increased due to commercial infrastructure expansion; Q1 2026 expenses expected comparable to Q4 2025 levels.
Last Updated: 01-04-2026, 03:12 am
Read Full TranscriptEarnings
Latest Release
31-03-2026
EPS / Forecast
3.14 / -0.52
Revenue / Forecast
86.5M / --
Compare OMER to Peers and Sector
Metrics to compare | OMER | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOMERPeersSector | |
|---|---|---|---|---|
P/E Ratio | −218.9x | 15.4x | −0.5x | |
PEG Ratio | −2.26 | 0.86 | 0.00 | |
Price/Book | −8.7x | 3.0x | 2.6x | |
Price / LTM Sales | - | 3.6x | 3.2x | |
Upside (Analyst Target) | 156.9% | 33.5% | 50.8% | |
Fair Value Upside | Unlock | 9.5% | 7.7% | Unlock |
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Omeros (OMER) Share Price Today?
The Omeros share price today is 14.600.
What is the current Omeros (OMER) share price and day range?
As of 30-04-2026, the Omeros share price is 14.600, with a previous close of 14.560. The share price has ranged from 14.575 to 14.920 today, while the 52-week range spans from 2.950 to 17.650.
What Is the Omeros Market Cap?
As of today, Omeros market cap is 1.050B.
What Is the Omeros (OMER) Share Price Target?
The average 12-month share price target for Omeros is 38.000, with a high estimate of 40 and a low estimate of 36. 2 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +160.27% Upside potential.
What Is Omeros's Earnings Per Share (TTM)?
The Omeros EPS (TTM) is -0.076.
When Is the Next Omeros Earnings Date?
Omeros will release its next earnings report on 12-05-2026.
From a Technical Analysis Perspective, Is OMER a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Omeros Trade On?
Omeros is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Omeros?
The stock symbol for Omeros is "OMER."
How Many Times Has Omeros Stock Split?
Omeros has split 0 times.
How Many Employees Does Omeros Have?
Omeros has 175 employees.
What Is the OMER Premarket Price?
OMER's last pre-market stock price is 14.650. The pre-market share volume is 5,350.000, and the stock has changed by 0.090, or 0.620%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.